Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Therapeutic Use
- 15 Oct 2018 Status changed to discontinued.
- 26 Jan 2017 Status changed from active, no longer recruiting to completed.
- 22 Dec 2016 Status changed from recruiting to active, no longer recruiting.